cGVHD. 12 pts have relapsed at a median of 128 days (range 76-512) post transplant with one year actuarial OS of 65%.

Conclusion: This approach permits accurate delivery of a targeted systemic exposure to IV busulfan, is well-tolerated, and will allow additional dose escalation. Relapse, as opposed to toxicity, remains the major challenge.

**274**

**TREOSULFAN: AN ATTRACTIVE ALTERNATIVE IN THE CONDITIONING IN BONE MARROW TRANSPLANTATION FOR THALASSEMIA**

Smiers, F.J.1, Bredius, R.1, Ball, L.1, Lankester, A.1, Bakker, H.1, Egeler, R.M.1 1Dept Pediatric Hemato Oncology and Bone Marrow Transplantation, Leiden University Hospital, Leiden, Netherlands; 2Data Management Dept Pediatric Hemato Oncology and Bone Marrow Transplantation, Leiden University Hospital, Leiden, Netherlands.

Traditionally Busulfan and Cyclofosfamide are used with or without serotherapy in the conditioning for beta thalassemia. Due to a high rejection rate in our institution, Melfalan has been added resulting in a marked reduction of rejection. Toxicity of this regimen is tolerable and consists mainly of mucositis and occasionally of VOD.

Treasulfan is an alkylating agent with a supposedly lower toxicity profile than other alkylating agents.

In 12 previously treated thalassemia patients (class 2-3) conditioned with Busulfan, Melfalan, Cyclofosfamide and serotherapy, mucositis WHO grade 1-2 was seen in 2 patients and grade 3-4 in 9 patients. VOD was seen in 4 patients and 2 patients had mild VOD. One patient died due to MOF. Acute GVHD was seen in 6 patients. Chronic GVHD (mild) in 2 patients. Two patients rejected but were successfully retransplanted. Ten patients had full donor chimerism, two patients showed stable mixed chimerism.

In comparison the results in 5 beta thalassemia patients (class 2-3) conditioned with Treosulfan 10 -14 mg/m2, Cyclofosfamide 120 mg/kg, Melfalan 140 mg/m2 with additional serotherapy (either ATG or Campath). Two patients had a matched unrelated donor, one patient matched related donor and one patient matched related donor but was successfully retransplanted. Ten patients received Treasulfan 10 mg/m2. One patient rejected early and was successfully retransplanted. Two patients received Treasulfan 14 mg/m2. The remaining two patients received Treasulfan 14 mg/m2. Engraftment was in normal range. No acute or chronic GVHD was seen. Mucositis was limited in 3 (WHO grade 2) and moderate to severe (WHO grade 1-4) in 2 patients. No VOD was seen. Chimerism was stable mixed in 2 and full donor in three.

**Conclusion:** Treasulfan 14 mg/m2 is well tolerated in thalassemia bone marrow transplant patients and shows a lower toxicity profile than busulfan.

**275**

**IMPACTS OF COMORBIDITIES ON OUTCOMES OF PATIENTS (PTS) YOUNGER THAN 60 YEARS OLD, DIAGNOSED WITH INDOLENT MALIGNANCIES AND TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT): A MODEL FOR PTS WITH AUTOIMMUNE DISEASES**

Sorror, M.L.1, Storb, R.1,2, Storer, B.1,2, Maloney, D.G.1,2, Sandmaier, B.M.1,2 1Fred Hutchinson Cancer Research Center; 2University of Washington, Seattle, WA.

The NIH has stated the growing need to explore the therapeutic and curative potential of allogeneic HCT for autoimmune diseases (BBMT 2005, 11:862). The safety of HCT in pts with significant comorbidities is of a concern. Here, we analyzed whether the HCT-CI, a sensitive tool to capture comorbidities (Blood 2005, 106:2912), could assess how young (<60 year old) pts with indolent malignancies tolerated allogeneic HCT strategies as a hypothetical model for pts with autoimmune diseases. A majority of pts received myeloablative (MA) conditioning (n=364) with cyclophosphamide plus busulfan (79%) or 12 Gy TBI (21%), while a small group of pts (n=79) received nonmyeloablative (NMA)-conditioning with 2 Gy total body irradiation (18%) ≥ 90 mg/m2 of fludarabine (82%). Diagnoses were acute myeloid leukemia in 1 remission (27%), chronic myeloid leukemia-chronic phase (40%), myelodysplasia-refractory anemia (16%), chronic lymphocytic leukemia (8%), low grade non-Hodgkin lymphoma (4%), and others (5%). At HCT, NMA-pts differed from MA-pts with respect to age (median 52 vs 41 years), prior high-dose HCT (9% vs 1%), unrelated grafts (42% vs 31%), and G-PRMC as stem cell source (87% vs 49%). HCT-CI scores of 1-2 and ≥3 were found among 33% and 35% of NMA vs 35% and 17% of MA-pts, respectively. The most frequent comorbidities were pulmonary (24%) and hepatic (16%). After HCT, 4-year cumulative incidences of non-relapse mortality (NRM) were 10%, 17%, and 36% for MA-pts with HCT-CI scores of 0, 1-2, and ≥3, respectively. Proportional hazards models adjusted for stem cell source, pt age, donor type, and diagnoses, were used to estimate hazard ratios (HR) for NRM and survival.

MA-pts with HCT-CI scores of 1-2 or ≥3 had higher adjusted HRs for NRM (1.85, p=0.06 and 4.56, p<0.0001) and all-cause mortality (2.15, p=0.003 and 4.59, p<0.0001) compared to pts with HCT-CI scores of 0. There were no statistically significant differences in NRM between NMA and MA-pts with HCT-CI scores of 0, 1-2, or ≥3 (p=0.7, p=0.1, p=0.18, respectively); however, the small numbers of pts receiving NMA conditioning in each stratum limited the power of these comparisons. We conclude that among young pts with indolent malignancies, NRM and survival are strongly associated with comorbidity after MA-HCT. Therefore, MA-HCT for treatment of autoimmune diseases might be contraindicated for pts with HCT-CI scores of ≥3. Additional data are needed to clarify the usefulness of NMA-HCT in indolent diseases.

**276**

**OUTCOME OF PATIENTS ACCORDING TO ETHNIC GROUPS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION IN MALAYSIA**

Tan, S.M.1, Chang, K.M.1, Ong, T.C.2, Salehi, S.3, Sathar, J.4, Prasothaban, V.5 1Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; 2Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia.

A total of 106 patients received an allogeneic stem cell transplantation at Kuala Lumpur Hospital between 5/1999 and 5/2006. Majority received G-CSF stimulated bone marrow as stem cell source while 20% received PBSC. The race distribution were 52% Malays, 31% Chinese, 9% Indians and 9% other races. The median time to neutrophil engraftment was 19 days and platelet engraftment was 18 days. There was no difference in engraftment days of platelets and neutrophils between G-CSF stimulated marrow and PBSC. The overall survival OS was 61%, event-free survival EFS was 54% and the 100-day transplant mortality rate TRM was 16%. The cumulative relapse rate was 24% and the graft-vs-host disease GVHD rate was 32%.

The overall survival rate according to race was 62% in Malys, 68% in Chinese and 50% in Indians. The cause for mortality in the Malay race was GVHD at 52%, relapse 29% and infection 29%. Amongst the Chinese, the major cause for mortality was relapse 60%, GVHD 20% and infection 10%. In the other races, the cause of mortality was relapse in 70% and GVHD in 20%.

The incidence of moderate Grade II and severe Grade III-IV acute GVHD was 40% and 29% in the Malays, 43% and 10% in the Chinese and 22% and 22% in the Indians respectively. Similarly the incidence of limited and extensive chronic GVHD was 12% and 34% in the Malays, 21% and 18% in the Chinese and 0% and 38% in the Indians.

It is evident that the incidence of severe acute GVHD and extensive chronic GVHD is higher in the Malays than the other races. Severe GVHD was also the major cause of mortality amongst the Malays than the other races. However the rate of relapse was inversely lower in the Malays than in the Chinese and Indians.

**277**

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN IMATINIB ERA: A SINGLE CENTER COMPARATIVE ANALYSIS OF IMATINIB RECEPTIVE PATIENTS TO IMATINIB NAIVE PATIENTS**

Uigur Bilgin, A.1, Soydan, E.1, Topcuoglu, P.1, Atilan, O.1, Ozcan, M.4, Gurman, G.1, Denizer, T.1, Akar, H.1, Bekac, M.1, Koutk, N.1, 1Hacettepe University School of Medicine, Ankara, Turkey; 2Hacettepe University Hospital, Ankara, Turkey; 3Tulane University School of Medicine, New Orleans, LA; 4Hacettepe University Faculty of Medicine, Ankara, Turkey.
728

HUMAN HERPESVIRUS-6 ENCEPHALITIS FOLLOWING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Vu, T.1,2,3, Kamble, R.5,6,7, Obiden, M.1,2,3, Schuloff, A.1,2,3, Ohi, G.1,2,3, East, K.1,2,3, Hutton, G.1,2,3, Heshp, H.1,2,3, Brenner, M.1,2,3, Carrum, G.1,2,3,1 Center for Cell and Gene Therapy, Houston, TX, 2 Baylor College of Medicine, Houston, TX, 3 The Methodist Hospital, Houston, TX.

Approximately 50% recipients of allo-HSCT develop human herpes virus-6 (HHV-6) viremia detectable by polymerase chain reaction amplification (HHV-6 PCR), but the clinical significance of this asymptomatic viremia is unclear. Five of 53(9.4%) patients who received Alemtuzumab (total dose, 40 mg) supported conditioning (CY-TBI = 3, BU-TBI = 1, Flu-Mel = 1, MUD = 1, MMRD = 1) and Tacrolimus as GVHD prophylaxis subsequently developed HHV-6 encephalitis whilst receiving antiviral prophylaxis (Valciclovir = 4 and Valganciclovir = 1). Acute GVHD (grade II = 1, grade III = 2, grade IV = 2) preceded encephalitis and had necessitated, prednisone = 5, Infliximab = 1, Alemtuzumab = 1, and Daclizumab = 1. HSV-6 encephalitis became apparent at 41-103 days (median 60 days) presenting with confusion (n=5), amnesia (n= 3) and seizures (n=2). MRI revealed non-specific white matter changes in 4 and a non enhancing medial temporal lobe lesion in one of the patients. CSF was elevated in 4 patients (table-1); CSF-pencloprotoxin was mild with a median of 3- lymphocytes/hpf. HSV-6 PCR on blood (plasma) revealed 100-225,500 (median 1200) DNA copies/ml. CSF PCR was positive in all 5 patients at 600-225,000 (median 4700) copies/ml. CSF HHV6 was several fold higher than plasma levels (table-1). EEG was nonspecific in all 5 patients. Intravenous administration of foscarnet resulted in neurological improvement at 8-13 (median 11) days and negative plasma PCR at 30-66 (median 50) days; recovery of short-term memory loss was more prolonged. In the patient with negative plasma PCR, CSF PCR became negative on 30th day of therapy. Four patients had complete neurological recovery; one patient (#2) had transient improvement before succumbing to multi-organ failure. We conclude that, HSV-6 encephalitis complicates approximately 10% of in vivo T cell depleted allo-HSCT. Poor yield of routine CSF, MRI and EEG examination calls for high index of suspicion and CSF examination for HHV-6 PCR. Prompt antiviral treatment with foscarnet appears effective.

Table-1: HSV-6 Encephalitis following allo-HSCT

<table>
<thead>
<tr>
<th>Age/ Sex/ Onset/ Days Follow-up</th>
<th>Manifestation</th>
<th>HSV-4 CSF (copiy/ml)</th>
<th>HSV-6 Blood (copiy/ml)</th>
<th>Outcome</th>
<th>Herpes infection Follow-up Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>46F +41</td>
<td>Amnesia, confusion, seizure</td>
<td>4700</td>
<td>Negative Complete</td>
<td>resolution</td>
<td>Zoster Alive 12 months</td>
</tr>
<tr>
<td>66F +103</td>
<td>Confusion, somnolence, disorganized speech</td>
<td>225,000</td>
<td>22,500</td>
<td>Transient improvement</td>
<td>CMV Died day = 147</td>
</tr>
<tr>
<td>41M +60</td>
<td>Amnesia, confusion, tremor</td>
<td>4000</td>
<td>100</td>
<td>Complete resolution None</td>
<td>Alive 36 months</td>
</tr>
<tr>
<td>39M +35</td>
<td>Amnesia, confusion, seizure</td>
<td>4000</td>
<td>100</td>
<td>Complete</td>
<td>BK virus resolution Alive 6 months</td>
</tr>
<tr>
<td>58F +83</td>
<td>Seizure, confusion</td>
<td>600</td>
<td>2700</td>
<td>Complete resolution</td>
<td>None Died day = 120</td>
</tr>
</tbody>
</table>

Abbreviations: M- male, F- female, allo-HSCT- allogeneic hematopoietic stem cell transplant, MRI- Magnetic resonance imaging, HHV- Human herpes virus, Prot- Protein, Leu- Leukocytes, CSF- Cerebrospinal fluid, WM- white matter, * Quantitative PCR not available

279

CD154:CD40 CO-STIMULATORY BLOCKADE AT PRIMARY BMT PROMOTES ALLOGENIC ENGRAFTMENT IN SECONDARY BMT BY BLOCKING DENSITIZATION

Xu, H.1, Huang, Y.1, Hussain, L-R.2, Yan, J.1, Ildstad, S.T.1 1 Institute for Cellular Therapeutics, University of Louisville, Louisville, KY.